Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to compare the mean AERP between treatment groups based on
the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological
remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to
placebo.